



FOR IMMEDIATE RELEASE

**Pierre Fabre Enters into License Agreement with Selexis SA to
Use SURE Technology Platform for Mammalian Cell Line Development
-- Pierre Fabre Will Use Technology to Research Therapeutic Candidates --**

Geneva, Switzerland – June 20, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic proteins, announced today that it has entered into a non-exclusive research license agreement with Institut de Recherche Pierre Fabre (IRPF) under which Pierre Fabre will have the rights to use Selexis' SURE Technology Platform to develop mammalian cell lines for use in the research of protein therapeutic candidates.

"As the third largest pharmaceutical company in France, Pierre Fabre's choice to use the SURE Technology Platform validates the impact Selexis' technologies are making in the pharma industry," said Dr. Igor Fisch, CEO of Selexis.

Under the terms of the license agreement, Pierre Fabre will have the right to internally use the SURE Technology Platform to engineer production cell lines for the research of Pierre Fabre protein therapeutic candidates. The financial details of the agreement were not disclosed.

Selexis' SURE Technology Platform, which includes the patented MARtech™, is a unique technology that improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. Based on proprietary human MAR (Matrix Attachment Region), MARtech™ enables cell population generation in just four weeks (after transfection) and stable cell line development in ten weeks (after transfection to first round of cell cloning). Additionally, MARtech™ has been found to significantly increase recombinant protein expression in mammalian cells in suspension and in serum-free up to twenty fold.

- more -

SELEXIS EUROPE
18 chemin des Aulx
1228 Plan-les-Ouates
Switzerland

T +41 (0)22 308 93 60
F +41 (0)22 308 93 61

SELEXIS USA
655 Montgomery Street, Suite 540
San Francisco, CA 94111
USA

T +1 415 273 5141
F +1 415 837 3204

“The SURE Technology Platform will able us to quickly develop high producing mammalian cell lines for antigen production, and as such to explore protein candidates in a more timely and cost effective manner.” said Dr. Nathalie Corvaia, Research Director, at the Pierre Fabre Immunology Center in Saint Julien-en-Genevois.”

About Selexis

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services. Selexis offers comprehensive and rapid solutions for the development of stable, high yield mammalian cell lines used in recombinant protein manufacturing. The Company's unique SURE cell line process, which includes Selexis' forth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit <http://www.selexis.com>

About Pierre Fabre Médicament R&D

The Pierre Fabre Group, the second largest independent laboratory in France, employs some 8620 people, and achieved 1.48 billion euros in sales in 2005. Operating in the area of ethical medicine, health products and dermo-cosmetic with the brands Avène, Ducray, A-derma, Galénic, Klorane and René Furterer, it achieves 44 % of its business abroad. Pierre Fabre Médicament, the pharmaceutical branch of the Pierre Fabre Group, made Research and Development its core business and the key to its future. With over 1 000 researchers, Pierre Fabre Médicament dedicates 25 % of its annual sales to R&D, in five major therapeutic areas in terms of public health: oncology (the priority R&D area of Pierre Fabre Médicament, with 50 % of all R&D expenses), central nervous system, cardiology, internal medicine/urology, dermatology.

This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.

Pierre Fabre Enters into License Agreement with Selexis SA

Page 3

MARtech™ is a trademark of Selexis, SA.

MEDIA CONTACT:

Robert Meister
602-953-1716
robert.meister@selexis.com

INSTITUT DE RECHERCHE PIERRE FABRE :

Caroline PERDRIX
33 1 49 10 80 00
Caroline.perdrix@pierre-fabre.com

MORE INFORMATION:

EUROPE
Igor Fisch, Ph.D.
41 (0)22 308 93 60
Igor.fisch@selexis.com

UNITED STATES
Cori Gorman, Ph.D., M.B.A.,
415-273-5141
cori.gorman@selexis.com

###